Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
about
Mineralocorticoid receptor blockade in chronic kidney diseaseAortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.Cardiorenal syndrome in acute heart failure syndromes.Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study.Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injuryAutophagy is involved in aldosterone‑induced mesangial cell proliferation.Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation - a cohort study from Sweden using propensity score analyses.Overexpressed cyclophilin B suppresses aldosterone-induced proximal tubular cell injury both in vitro and in vivo.Mineralocorticoid receptor blockade in chronic kidney disease.Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.Feline CKD: Pathophysiology and risk factors--what do we know?Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients.NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury.Effective medical treatment strategies to help cessation of purging behaviors.Reduction of diuretics and analysis of water and muscle volumes to prevent falls and fall-related fractures in older adults.Renal tissue oxygenation in essential hypertension and chronic kidney diseaseEffect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study.Reactive oxygen species-initiated autophagy opposes aldosterone-induced podocyte injury.Defining obesity hypoventilation syndrome.Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.Association of body mass index and left ventricular mass index with abnormally low and high ankle-brachial indices in chronic kidney disease.Pharmacotherapy and mortality in atrial fibrillation--a cohort of men and women 75 years or older in Sweden.Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC).Consensus Recommendations for Standard Therapy of Glomerular Disease in DogsAldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and PathophysiologyLipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury
P2860
Q26864370-C1199477-1DDF-4107-B1B1-8E1ECACAFE97Q34512883-8C6C0A73-DEB1-4606-B687-A6D69150A225Q34665867-C6AC205F-7464-4548-80DC-238D61531041Q34751971-7BBD5D6C-5A49-4A7D-968D-0FA33609521BQ35208686-68DE0EFA-F91E-4C5D-87BE-22D223175AACQ35272248-501E7DB2-3CCF-4C7D-BC73-31716D11E1FFQ36050919-9E674B99-B901-461C-BDED-CED9980F8163Q37403582-85235F90-722E-414C-949A-E1F49A228023Q37479988-6F1F5F05-E098-43D9-9AE7-714D127616A1Q37688358-753E3E43-52F5-4215-9BAB-11F9151E7226Q37861583-1B10EA0B-9187-4863-A19C-E3656F472D12Q37976974-D9A59FCB-2FB2-4A59-8899-BC5618E79AE0Q38105019-533D75AF-0CDE-4503-8054-0ABBB28BA1ACQ38133696-44BFE242-1F54-4A9A-BFD3-147B53BB9FF9Q38393182-361D9D4C-D2D3-4869-A699-F5624EB6DDA9Q38722963-E04AB4EB-DE1E-4F79-ADF4-FDA3C5B1F0A2Q38733027-CF21F115-0EBA-4690-95B4-A92E7D8D1D15Q39177152-9D80B16E-CB32-499F-A3DF-DE9BBA2F98A5Q41498684-0404BB1D-1098-4047-B14F-5986521B7DCCQ45813085-AAFE2A45-B235-487F-89C2-002AA817E67EQ46611165-2E34BD1C-B8AA-4051-87BA-F91B08D8814CQ48133681-6EBB36C6-BDD2-4140-927D-9E38DEE8DCB9Q48317107-02B7F6E7-5359-41FB-A485-374E07AF80FEQ48453795-C5F3842E-8943-4FC8-9D52-3985E7FF45F5Q51649113-CD6A5190-43B4-48DE-8ADF-4B8730997C57Q54654128-19CC2E1E-478A-437D-B72E-D3483820B93AQ55344755-B43F7048-9E3C-4C92-BB67-FA3C52D9A314Q57425110-5E385332-4E98-4D5F-9687-ADAE68AFA642Q57493008-261C0CE7-7F34-45AE-ABAC-62457F0522DFQ58760700-C5EFCB26-75EB-4537-B1F6-840326F8AB7F
P2860
Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@en
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@nl
type
label
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@en
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@nl
prefLabel
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@en
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@nl
P356
P1476
Aldosterone: role in edematous ...... ilure, and metabolic syndrome.
@en
P2093
Amirali Masoumi
Elwaleed Elhassan
P304
P356
10.2215/CJN.01410210
P577
2010-05-06T00:00:00Z